PE20221281A1 - Formulaciones de anticuerpos anti-pd-l1 - Google Patents
Formulaciones de anticuerpos anti-pd-l1Info
- Publication number
- PE20221281A1 PE20221281A1 PE2022001036A PE2022001036A PE20221281A1 PE 20221281 A1 PE20221281 A1 PE 20221281A1 PE 2022001036 A PE2022001036 A PE 2022001036A PE 2022001036 A PE2022001036 A PE 2022001036A PE 20221281 A1 PE20221281 A1 PE 20221281A1
- Authority
- PE
- Peru
- Prior art keywords
- hvr
- seq
- amino acid
- acid sequence
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referida a una formulacion farmaceutica liquida que comprende un anticuerpo monoclonal anti-PD-L1 en una concentracion de 100 g/l a 150 g/l, acetato de histidina en una concentracion de 15 mM a 25 mM, sacarosa en una concentracion de 200 mM a 280 mM, polisorbato en una concentracion de 0,04 % (p/v) a 0,08 % (p/v), metionina en una concentracion de 5 mM a 15 mM y pH de 5,6 a 6,0, en la que el anticuerpo monoclonal comprende (a) una region variable de la cadena ligera que comprende: (1) HVR-L1 que comprende la secuencia de aminoacidos RASQDVSTAVA (SEQ ID NO: 1); (2) HVR-L2 que comprende la secuencia de aminoacidos SASFLYS (SEQ ID NO:2); (3) HVR-L3 que comprende la secuencia de aminoacidos QQYLYHPAT (SEQ ID NO:3); y (b) una region variable de la cadena pesada que comprende: (1) HVR-H1 que comprende la secuencia de aminoacidos GFTFSDSWIH (SEQ ID NO:4); (2) HVR-H2 que comprende la secuencia de aminoacidos AWISPYGGSTYYADSVKG (SEQ ID NO:5); (3) HVR-H3 que comprende la secuencia de aminoacidos WPGGFDY (SEQ ID NO:6).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945730P | 2019-12-09 | 2019-12-09 | |
| PCT/US2020/063620 WO2021118930A2 (en) | 2019-12-09 | 2020-12-07 | Anti-pd-l1 antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221281A1 true PE20221281A1 (es) | 2022-09-05 |
Family
ID=74206149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001036A PE20221281A1 (es) | 2019-12-09 | 2020-12-07 | Formulaciones de anticuerpos anti-pd-l1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230039268A1 (es) |
| EP (1) | EP4073120A2 (es) |
| JP (1) | JP2023504748A (es) |
| KR (1) | KR20220113414A (es) |
| CN (1) | CN114787191A (es) |
| AU (1) | AU2020399619A1 (es) |
| BR (1) | BR112022011228A2 (es) |
| CA (1) | CA3158987A1 (es) |
| CL (2) | CL2022001486A1 (es) |
| CR (1) | CR20220322A (es) |
| IL (1) | IL293580A (es) |
| MX (1) | MX2022006784A (es) |
| PE (1) | PE20221281A1 (es) |
| TW (1) | TW202128223A (es) |
| WO (1) | WO2021118930A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122665A1 (en) | 2021-12-22 | 2023-06-29 | Genentech, Inc. | Clinical formulations of anti-tigit antibodies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| IL136544A0 (en) | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| SG177008A1 (en) | 2003-03-05 | 2012-01-30 | Halozyme Inc | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| TWI686405B (zh) | 2008-12-09 | 2020-03-01 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| MA38960A1 (fr) | 2013-09-27 | 2017-10-31 | Genentech Inc | Formulations d'anticorps anti-pdl1 |
| CN110167594B (zh) * | 2017-01-17 | 2023-11-21 | 豪夫迈·罗氏有限公司 | 皮下her2抗体配制剂 |
-
2020
- 2020-12-07 JP JP2022534224A patent/JP2023504748A/ja active Pending
- 2020-12-07 KR KR1020227021568A patent/KR20220113414A/ko unknown
- 2020-12-07 IL IL293580A patent/IL293580A/en unknown
- 2020-12-07 EP EP20845457.9A patent/EP4073120A2/en active Pending
- 2020-12-07 CN CN202080085014.1A patent/CN114787191A/zh active Pending
- 2020-12-07 CR CR20220322A patent/CR20220322A/es unknown
- 2020-12-07 US US17/783,229 patent/US20230039268A1/en active Pending
- 2020-12-07 CA CA3158987A patent/CA3158987A1/en active Pending
- 2020-12-07 BR BR112022011228A patent/BR112022011228A2/pt unknown
- 2020-12-07 PE PE2022001036A patent/PE20221281A1/es unknown
- 2020-12-07 MX MX2022006784A patent/MX2022006784A/es unknown
- 2020-12-07 AU AU2020399619A patent/AU2020399619A1/en active Pending
- 2020-12-07 WO PCT/US2020/063620 patent/WO2021118930A2/en active Application Filing
- 2020-12-09 TW TW109143376A patent/TW202128223A/zh unknown
-
2022
- 2022-06-06 CL CL2022001486A patent/CL2022001486A1/es unknown
-
2023
- 2023-04-20 CL CL2023001140A patent/CL2023001140A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL293580A (en) | 2022-08-01 |
| CR20220322A (es) | 2022-07-28 |
| KR20220113414A (ko) | 2022-08-12 |
| JP2023504748A (ja) | 2023-02-06 |
| AU2020399619A1 (en) | 2022-06-09 |
| WO2021118930A2 (en) | 2021-06-17 |
| WO2021118930A3 (en) | 2021-08-19 |
| EP4073120A2 (en) | 2022-10-19 |
| CN114787191A (zh) | 2022-07-22 |
| CA3158987A1 (en) | 2021-06-17 |
| US20230039268A1 (en) | 2023-02-09 |
| CL2023001140A1 (es) | 2023-10-06 |
| CL2022001486A1 (es) | 2023-01-20 |
| TW202128223A (zh) | 2021-08-01 |
| BR112022011228A2 (pt) | 2022-10-11 |
| MX2022006784A (es) | 2022-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121023A1 (es) | Anticuerpos e inmunoconjugados | |
| HRP20201493T1 (hr) | Anti-alfa-sinukleinska protutijela i postupci uporabe | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| AR088579A1 (es) | Formulaciones de anticuerpos | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| CO6331344A2 (es) | Anticuerpos aislados que unen a vegf, composiciones farmaceuticas que los comprenden y un portador farmaceuticamente aceptable y usos de los mismos | |
| JP2020518600A5 (es) | ||
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| PE20120553A1 (es) | Anticuerpos anti-fgfr3 | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| JP2020500538A5 (es) | ||
| PH12018500708A1 (en) | Humanized anti-human cd19 antibodies and methods of use | |
| JP2016533335A5 (es) | ||
| AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| AR099855A1 (es) | Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso | |
| NZ602040A (en) | Anti-lrp6 antibodies | |
| PE20141114A1 (es) | Anticuerpos anti-mesotelina e inmunoconjugados | |
| PE20170670A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| JP2017514461A5 (es) | ||
| ES2628108T3 (es) | Anticuerpos multiespecíficos | |
| JP2020518598A5 (es) | ||
| MY182680A (en) | Antibody formulation and therapeutic regimens | |
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| PE20150945A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
| PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos |